Sun Pharmaceutical Industries Limited

NSEI:SUNPHARMA Voorraadrapport

Marktkapitalisatie: ₹4.4t

Sun Pharmaceutical Industries Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Dilip Shanghvi

Algemeen directeur

₹60.5m

Totale compensatie

Percentage CEO-salaris75.6%
Dienstverband CEO31.7yrs
Eigendom CEO9.6%
Management gemiddelde ambtstermijn2.8yrs
Gemiddelde ambtstermijn bestuur3.5yrs

Recente managementupdates

This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Jul 30
This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Recent updates

Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Oct 31
Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease

Oct 21
We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease

Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now

Aug 24
Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now

Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

Aug 06
Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Jul 30
This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth

Jun 30
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Jun 12
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

May 25
Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings

May 22
Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Mar 13
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Feb 03
Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today

Jan 05
Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today

Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely

Dec 18
Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely

Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?

Oct 04
Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?

Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?

Jul 03
Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?

We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease

Jun 15
We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease

Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?

Mar 14
Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50

Feb 03
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well

Dec 09
These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well

Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?

Oct 13
Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely

Sep 04
These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Aug 05
Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Analyse CEO-vergoeding

Hoe is Dilip Shanghvi's beloning veranderd ten opzichte van Sun Pharmaceutical Industries's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

₹111b

Jun 30 2024n/an/a

₹104b

Mar 31 2024₹61m₹46m

₹96b

Dec 31 2023n/an/a

₹89b

Sep 30 2023n/an/a

₹85b

Jun 30 2023n/an/a

₹84b

Mar 31 2023₹55m₹41m

₹85b

Dec 31 2022n/an/a

₹42b

Sep 30 2022n/an/a

₹41b

Jun 30 2022n/an/a

₹39b

Mar 31 2022₹51m₹38m

₹33b

Dec 31 2021n/an/a

₹64b

Sep 30 2021n/an/a

₹62b

Jun 30 2021n/an/a

₹60b

Mar 31 2021₹46m₹35m

₹29b

Dec 31 2020n/an/a

₹24b

Sep 30 2020n/an/a

₹15b

Jun 30 2020n/an/a

₹7b

Mar 31 2020₹43m₹32m

₹38b

Dec 31 2019n/an/a

₹40b

Sep 30 2019n/an/a

₹43b

Jun 30 2019n/an/a

₹30b

Mar 31 2019₹263k₹1

₹27b

Dec 31 2018n/an/a

₹34b

Sep 30 2018n/an/a

₹24b

Jun 30 2018n/an/a

₹36b

Mar 31 2018₹34m₹28m

₹21b

Compensatie versus markt: De totale vergoeding ($USD 720.15K ) Dilip } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 1.11M ).

Compensatie versus inkomsten: De vergoeding van Dilip is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Dilip Shanghvi (69 yo)

31.7yrs

Tenure

₹60,541,920

Compensatie

Mr. Dilip Shantilal Shanghvi serves as MD at Sun Petrochemicals Private Limited. He serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He se...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Dilip Shanghvi
MD & Chairman of the Boardno data₹60.54m9.6%
₹ 426.0b
Aalok Shanghvi
Executive VPno data₹68.75m0.12%
₹ 5.3b
C. Muralidharan
Chief Financial Officer7.4yrs₹38.89mgeen gegevens
Davinder Singh
Executive Vice-President of Global Operationsno datageen gegevensgeen gegevens
Dheeraj Sinha
EVP & Chief Information Officerless than a yeargeen gegevensgeen gegevens
Abhishek Sharma
VP, Head of Investor Relations & Strategic Projectsno datageen gegevensgeen gegevens
Anoop Deshpande
Company Secretary & Compliance Officer2.8yrsgeen gegevensgeen gegevens
Kalyanasundaram Subramanian
Director of Corporate Developmentno data₹65.30mgeen gegevens
Suresh Rai
Chief Human Resources Officerless than a yeargeen gegevensgeen gegevens
Kirti Ganorkar
Head of India Businessno datageen gegevensgeen gegevens
Abhay Gandhi
Chief Executive Officer of North America Business8.3yrsgeen gegevensgeen gegevens
Azadar Hussain Asghar Khan
Head of Corporate Relations & CSR - India Regulatory Affairsno datageen gegevensgeen gegevens

2.8yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SUNPHARMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Dilip Shanghvi
MD & Chairman of the Board31.7yrs₹60.54m9.6%
₹ 426.0b
Aalok Shanghvi
Executive VP1.4yrs₹68.75m0.12%
₹ 5.3b
Sudhir Valia
Non-Executive & Non-Independent Director30.8yrs₹2.20m1.8%
₹ 79.8b
Rama Bijapurkar
Non-Executive & Independent Director3.5yrs₹5.10mgeen gegevens
Gautam Doshi
Non-Executive Independent Director6.5yrs₹7.80mgeen gegevens
Rolf Hoffmann
Independent Director1.4yrs₹3.20mgeen gegevens
Pawan Goenka
Lead Independent Director3.5yrs₹8.50mgeen gegevens
Sanjay Asher
Independent Director2yrs₹4.80mgeen gegevens

3.5yrs

Gemiddelde duur

67.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SUNPHARMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).